|Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry (PERI-DYS)
ClinicalTrials.gov Identifier: NCT03110432
|Prospective observational registry. Patients will receive either standard lipid lowering therapy (statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids and any combinations of these agents), or a PCSK9 inhibitor. The duration of the study is 3 years.
|2000 patients with dyslipidemia with very high cardiovascular risk who principally meet the Gemeinsamer Bundesausschuss (G-BA) stipulations for PCSK9 use, and are treated by office-based cardiologists or in lipid ambulances.
|LDL cholesterol goal achievement < 70 mg/dl at 3 years